Shoker Investment Counsel’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.62M Sell
21,218
-754
-3% -$167K 1.37% 18
2025
Q4
$5.02M Sell
21,972
-667
-3% -$152K 1.47% 16
2025
Q3
$5.24M Sell
22,639
-90
-0.4% -$18.3K 1.55% 15
2025
Q2
$4.22M Sell
22,729
-475
-2% -$88.3K 1.32% 17
2025
Q1
$4.86M Buy
23,204
+118
+0.5% +$22.9K 1.64% 12
2024
Q4
$4.1M Sell
23,086
-306
-1% -$56.3K 1.39% 17
2024
Q3
$4.62M Sell
23,392
-647
-3% -$121K 1.55% 14
2024
Q2
$4.12M Sell
24,039
-879
-4% -$146K 1.46% 15
2024
Q1
$4.5M Buy
24,918
+142
+0.6% +$24.5K 1.61% 14
2023
Q4
$3.84M Buy
24,776
+110
+0.4% +$16K 1.48% 15
2023
Q3
$3.68M Sell
24,666
-104
-0.4% -$15.3K 1.6% 15
2023
Q2
$3.34M Sell
24,770
-7
-0% -$1.03K 1.39% 17
2023
Q1
$3.95M Sell
24,777
-21
-0.1% -$3.21K 1.72% 13
2022
Q4
$4.01M Sell
24,798
-870
-3% -$133K 1.8% 11
2022
Q3
$3.44M Buy
25,668
+504
+2% +$72.3K 1.81% 16
2022
Q2
$3.85M Sell
25,164
-133
-0.5% -$20.3K 2.05% 8
2022
Q1
$4.1M Sell
25,297
-96
-0.4% -$13.9K 2.03% 9
2021
Q4
$3.44M Sell
25,393
-610
-2% -$72.1K 1.58% 16
2021
Q3
$2.8M Buy
26,003
+400
+2% +$45.7K 1.4% 19
2021
Q2
$2.88M Buy
25,603
+354
+1% +$39.9K 1.44% 18
2021
Q1
$2.73M Sell
25,249
-2,757
-10% -$295K 1.43% 19
2020
Q4
$3M Buy
28,006
+194
+0.7% +$18.6K 1.68% 13
2020
Q3
$2.44M Buy
27,812
+94
+0.3% +$8.85K 1.6% 18
2020
Q2
$2.72M Buy
27,718
+255
+0.9% +$22.5K 1.9% 13
2020
Q1
$2.09M Buy
27,463
+1,113
+4% +$94.8K 1.76% 16
2019
Q4
$2.33M Buy
26,350
+239
+0.9% +$19.8K 1.55% 17
2019
Q3
$1.98M Buy
26,111
+1,574
+6% +$108K 1.42% 22
2019
Q2
$1.78M Buy
24,537
+1,220
+5% +$95.9K 1.3% 27
2019
Q1
$1.88M Buy
23,317
+219
+0.9% +$17.9K 1.39% 19
2018
Q4
$2.13M Buy
23,098
+204
+0.9% +$17.9K 1.79% 16
2018
Q3
$2.17M Buy
22,894
+15
+0.1% +$1.42K 1.57% 17
2018
Q2
$2.12M Sell
22,879
-397
-2% -$38.8K 1.58% 17
2018
Q1
$2.2M Sell
23,276
-1,121
-5% -$123K 1.67% 15
2017
Q4
$2.36M Sell
24,397
-1,041
-4% -$98.1K 1.7% 13
2017
Q3
$2.26M Sell
25,438
-311
-1% -$23.7K 1.71% 14
2017
Q2
$1.87M Buy
25,749
+1,455
+6% +$97.8K 1.47% 19
2017
Q1
$1.58M Sell
24,294
-1,690
-7% -$106K 1.33% 24
2016
Q4
$1.63M Buy
25,984
+709
+3% +$43.3K 1.35% 22
2016
Q3
$1.59M Sell
25,275
-223
-0.9% -$14.4K 1.35% 21
2016
Q2
$1.58M Sell
25,498
-21
-0.1% -$1.28K 1.4% 20
2016
Q1
$1.46M Sell
25,519
-274
-1% -$15.3K 1.37% 22
2015
Q4
$1.53M Buy
25,793
+651
+3% +$37.5K 1.53% 22
2015
Q3
$1.37M Sell
25,142
-678
-3% -$44.1K 1.44% 19
2015
Q2
$1.73M Sell
25,820
-721
-3% -$47.1K 1.63% 18
2015
Q1
$1.55M Buy
26,541
+171
+0.6% +$10.3K 1.48% 19
2014
Q4
$1.73M Buy
26,370
+359
+1% +$22.6K 1.6% 18
2014
Q3
$1.5M Buy
26,011
+150
+0.6% +$8.33K 1.39% 22
2014
Q2
$1.46M Buy
25,861
+462
+2% +$24.2K 1.29% 26
2014
Q1
$1.31M Buy
25,399
+208
+0.8% +$10.5K 1.23% 27
2013
Q4
$1.33M Buy
+25,191
New +$1.24M 1.22% 26

Other funds holding ABBV

Shoker Investment Counsel's ABBV Position: Q1 2026 in Review

Shoker Investment Counsel reduced its AbbVie (ABBV) stake by 3.4% in Q1 2026, selling an estimated $167K and leaving 21,218 shares worth $4.62M. The position accounts for 1.37% of the portfolio, ranked #18.

Shoker Investment Counsel first reported a position in ABBV in Q4 2013 and has held it in 50 quarters since. The position peaked at $5.24M in Q3 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Shoker Investment Counsel held 21,218 shares of AbbVie worth $4.62M as of Q1 2026.
  • Shoker Investment Counsel sold 754 AbbVie shares in Q1 2026, an estimated $167K.
  • AbbVie made up 1.37% of Shoker Investment Counsel's portfolio in Q1 2026, its #18 holding.
  • Shoker Investment Counsel first reported a position in AbbVie in Q4 2013 and has held it in 50 quarters since.
  • Shoker Investment Counsel's AbbVie position peaked at $5.24M in Q3 2025.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Shoker Investment Counsel's 13F filing for Q1 2026, filed 11 May 2026.